Attached files

file filename
EX-10.21 - EXHIBIT 10.21 - SEELOS THERAPEUTICS, INC.apri123116ex1021.htm
EX-99.2 - EXHIBIT 99.2 - SEELOS THERAPEUTICS, INC.apri123116ex992.htm
EX-31.1 - EXHIBIT 31.1 - SEELOS THERAPEUTICS, INC.apri123116ex311.htm
EX-23.1 - EXHIBIT 23.1 - SEELOS THERAPEUTICS, INC.apri12312016ex231bdo.htm
EX-21 - EXHIBIT 21 - SEELOS THERAPEUTICS, INC.apri123116ex21.htm
EX-10.22 - EXHIBIT 10.22 - SEELOS THERAPEUTICS, INC.apri123116ex1022.htm
EX-10.2 - EXHIBIT 10.20 - SEELOS THERAPEUTICS, INC.apri123116ex1020.htm
10-K - APRI 12.31.16 10-K - SEELOS THERAPEUTICS, INC.apri12311610k.htm


Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Richard W. Pascoe, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Apricus Biosciences, Inc. on Form 10-K for the year ended December 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Apricus Biosciences, Inc.
 
Date: March 13, 2017
By:
/S/ RICHARD W. PASCOE
 
Name:
Richard W. Pascoe
 
Title:
Chief Executive Officer & Secretary